Susanne Liptay

Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B.

Transcription factors of the NF-kappaB/Rel family are critical for inducible expression of multiple genes involved in inflammatory responses. Sulfasalazine and its salicylate moiety 5-aminosalicylic acid are among the most effective agents for treating inflammatory bowel disease and rheumatoid arthritis. However, the mode of action of these drugs remains unclear. Here we provide evidence that the transcription factor NF-kappaB is a target of sulfasalazine-mediated immunosuppression. Treatment of SW620 colon cells with sulfasalazine inhibited TNFalpha-, LPS-, or phorbol ester- induced NF-kappaB activation. NF-kappaB-dependent transcription was inhibited by sulfasalazine at micro- to millimolar concentrations. In contrast, 5-aminosalicylic acid or sulfapyridine did not block NF-kappaB activation at all doses tested. TNFalpha-induced nuclear translocation of NF-kappaB was prevented by sulfasalazine through inhibition of IkappaBalpha degradation. When blocking proteasome-mediated degradation of IkappaBalpha, we could demonstrate that sulfasalazine interfered with IkappaBalpha phosphorylation, suggesting a direct effect on an IkappaBalpha kinase or on an upstream signal. Inhibition of NF-kappaB activation seems to be specific since other DNA-binding activities such as AP1 were not affected. These results demonstrate that sulfasalazine is a potent and specific inhibitor of NF-kappaB activation, and thus may explain some of the known biological properties of sulfasalazine.

Recombinant platelet-derived growth factor B gene expression in porcine arteries induce intimal hyperplasia in vivo.

Platelet-derived growth factor (PDGF) B chain induces cell proliferation in vitro and is associated with arterial lesions that cause cardiovascular disease. However, it has been difficult to document the biological response to PDGF B gene expression in arteries in vivo. To determine the biologic effects of this growth factor in vivo, we have introduced an eukaryotic expression vector plasmid encoding recombinant PDGF B by direct gene transfer into porcine iliofemoral arteries using DNA liposome complexes. The presence of PDGF B plasmid DNA and expression of recombinant mRNA were confirmed by polymerase chain reaction analysis, and recombinant PDGF protein was demonstrated by immunohistochemistry. Intimal thickening was observed in porcine arteries 21 days following transfection with the recombinant PDGF B gene compared with arteries transduced with a control gene, E. coli beta-galactosidase. An eightfold increase in intimal to medial ratio was present in PDGF B gene transfected arteries compared with control transfected arteries (P = 0.001). This study suggests that expression of a recombinant PDGF B gene in vivo can play a role in the induction of intimal hyperplasia, which can lead to cardiovascular diseases.

p300 Acts as a Transcriptional Coactivator for Mammalian Notch-1

ABSTRACT Notch-1 belongs to a family of transmembrane receptor proteins that direct the decisions as to various cell fates. After ligand binding, a proteolytic cleavage step occurs and the intracellular part of Notch-1, Notch-1-IC, translocates into the nucleus, where it targets the DNA binding protein RBP-Jκ/CBF1. RBP-Jκ mediates repression through recruitment of a histone deacetylase-containing complex. The Notch-1-IC/RBP-Jκ complex overcomes repression and activates the transcription of Notch target genes. We have identified a novel domain in Notch-1-IC, the EP domain, which is indispensable for full transcriptional activation. This transactivation domain is localized adjacent to the ankyrin repeats of Notch-1-IC. In cotransfection experiments, Notch-1-IC-mediated transcriptional activation was inhibited by E1A12S and p53, two proteins, which interfere with the function of the common coactivator p300. Protein-protein interaction assays demonstrated the association of Notch-1-IC and the CH3 region of p300. In addition, the interaction of mammalian Notch-1-IC with p300 was destabilized after deletion of the EP domain of Notch-1-IC. Based on physical interaction with Notch-1-IC and coactivator functions of p300, we propose a model for Notch-1-mediated gene regulation via p300.

Transcriptional regulation of NF-kappa B2: evidence for kappa B-mediated positive and negative autoregulation.

NF-kappa B is an inducible transcription factor complex which regulates the expression of a variety of genes which are involved in the immune, inflammatory, and acute-phase responses. The maintenance of NF-kappa B activity in stimulated cells requires ongoing protein synthesis, suggesting several modes of regulation. In this report, we have characterized the transcriptional regulation of one family member, NF-kappa B2. The genomic structure and sequence of NF-kappa B2 revealed the presence of two promoters and at least four kappa B regulatory elements, which mediate responsiveness to phorbol myristate acetate and tumor necrosis factor alpha. Similar to other NF-kappa B family members, NF-kappa B2 is positively autoregulated. In contrast to other family members, we find that kappa B elements in the NFKB2 promoter can also mediate transcriptional repression in the absence of NF-kappa B. We identified a nuclear complex which binds specifically to a subset of kappa B-related sites but not to the canonical kappa B element. Because of its putative inhibitory or repressive effect, this binding activity has been termed Rep-kappa B. This mechanism of repressing basal NF-kappa B2 transcription in an inactivated state enables the cell to tightly control NF-kappa B2 activity. These data demonstrate that a novel mode of kappa B-dependent regulation is mediated by specific kappa B sites in the NFKB2 promoter.

Transforming growth factor alpha activates Ha-Ras in human pancreatic cancer cells with Ki-ras mutations.

BACKGROUND & AIMS The aim of this study was to identify signaling pathways that mediate cell proliferation in response to a Ras-activating growth factor, transforming growth factor (TGF)-alpha, in two pancreatic cancer cell lines with constitutively active Ki-Ras, MiaPaCa-2, and Panc-1. METHODS ERK1/-2- and p90(rsk) activation were determined by immune complex kinase assays. AP-1 and E74 activation were assessed in transient transfections using luciferase reporter plasmids. Ha-Ras activation was determined using a glutathione S-transferase fusion protein comprising the Ras-binding domain of Raf and by immunocytochemistry, growth by DNA synthesis and colony formation in softagar. RESULTS TGF-alpha stimulated activation of ERK1/-2, which was dependent on MEK-1, but independent of PKC activity. TGF-alpha-induced activation of an AP-1 reporter plasmid also required MEK-1 and Ras activity. Using an E74 reporter plasmid, we demonstrate that TGF-alpha indeed activates Ras in both cell lines. In particular, TGF-alpha induced membrane translocation and activation of the Ras isoform Ha-Ras. Finally, TGF-alpha-stimulated DNA synthesis and clonal growth in soft agar were prevented by treatment of cells with a MEK-1 inhibitor or a Ras farnesyl transferase inhibitor. CONCLUSIONS The Ha-Ras-ERK cascade plays an important role in TGF-alpha-induced growth of pancreatic cancer cells with activating Ki-ras mutations. Inhibitors of this cascade could constitute novel anticancer agents for pancreatic tumors.

Related subunits of NF-κB map to two distinct loci associated with translocations in leukemia, NFKB1 and NFKB2

The chromosomal locations of the human genes NFKB1 and NFKB2, which encode two alternative DNA binding subunits of the NF-kappa B complex, p105 and p49/p100, respectively, have been determined. p105 was assigned to 4q21.1-q24 and p49/p100 to chromosome 10 by Southern blot analysis of panels of human/Chinese hamster cell hybrids. The locations were confirmed by fluorescence in situ hybridization and mapped with greater resolution to 4q23 and 10q24, respectively. These results demonstrate that these members of the NF-kappa B family are unlinked. Interestingly, p49/p100 as well as p105 maps to regions associated with certain types of acute lymphoblastic leukemia.

Colon Epithelium Can Be Transiently Transfected with Liposomes, Calcium Phosphate Precipitation and DEAE Dextran in vivo

Background: The introduction of recombinant DNA into cells is the initial step toward the development of gene therapy. It has been shown that cationic liposomes are useful vehicles to introduce DNA into colon epithelial cells in vivo. Methods: In the present study we compared the efficacy of different nonviral transfection methods into the colon wall. In anesthetized rats, a double balloon catheter was advanced into the colon and a chloramphenicol acetyltransferase (CAT) reporter plasmid complexed to liposomes, mixed with DEAE dextran, or precipitated with calcium phosphate was instilled. Following 2 days CAT activity was determined in the transfected colon segments. Results: DEAE dextran and liposomes were more effective than calcium phosphate, whereas naked DNA was not taken up by the colon epithelial cells. Reporter gene expression was dose-dependent. Expressing cell types did not differ utilizing the various transfection methods as judged by X-gal staining of colon sections after transfection with a LacZ reporter plasmid. Conclusion: These data indicate that in addition to liposomes, plasmid DNA mixed with DEAE dextran can be taken up by colon epithelial cells. This transfection techniques may prove useful in the development of gene therapy approaches for colon disease.

Sulfasalazine is a potent and specific inhibitor of IKB-kinases IKKa and IKKb

Background & Aims: NF-KBlRel has been implicated in the pathogenesis of inflammatory bowel disease (IBD). Various drugs known to be effective for the treatment of IBD such as glucocorticoids and salicylates have been shown to interfere with NF-KBlRel signaling. The aim of this study was to define the molecular mechanism by which sulfasalazine inhibits NF-KB activation. Methods: The effects of sulfasalazine and its moieties on NF-KB signaling were evaluated using electromobility shift-, transfectionand immune complex kinase-assays. The direct effect of sulfasalazine on IKB kinase (IKK) activity was investigated using purified recombinant IKKaand IKKl3proteins. Results: NF-kBlRel activity induced by the overexpression of NF-KBinducing kinase (NIK), IKKa, IKKI3, or consitutively active IKKaand IKKl3mutants was inhibited in a dose dependent manner by sulfasalazine. Sulfasalazine inhibited TNFa, PMA and IL-I induced activation of endogenous IKKs in colonic epithelial and Jurkat T cells. Sulfasalazine did not affect other cell1ular kinases such as MAP-kinases JNK and p38. Sulfasalazine diminished the catalytic activity of purified IKKaand IKKl3in vitro. In contrast, the metabolic moieties of sulfasalazine, 5-aminosalicylic acid and sulfapyridine were not effective. The decrease in substrate phosphorylation by IKKaandl3is associated with a decrease of autophosphorylation of IKKs and can be antagonized by excess ATP. Conclusions: These data suggest that sulfasalazine is a competitive antagonist of ATP binding of IKKaand IKKI3. This suppression of NF-kB activation by inhibition of IKK activity may contribute to the well-known anti-inflammatory and immunosuppressive effects of sulfasalazine.